ATE533781T1 - Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten - Google Patents

Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten

Info

Publication number
ATE533781T1
ATE533781T1 AT06743556T AT06743556T ATE533781T1 AT E533781 T1 ATE533781 T1 AT E533781T1 AT 06743556 T AT06743556 T AT 06743556T AT 06743556 T AT06743556 T AT 06743556T AT E533781 T1 ATE533781 T1 AT E533781T1
Authority
AT
Austria
Prior art keywords
bone morphogenetic
morphogenetic protein
binding site
heparin binding
same
Prior art date
Application number
AT06743556T
Other languages
English (en)
Inventor
Elli Birr
Mari Ulmanen
Oili Hietala
Marja Juustila
Heli Korkala
Pekka Jalovaara
Original Assignee
Bbs Bioactive Bone Substitutes Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20055256A external-priority patent/FI118736B/fi
Priority claimed from FI20055257A external-priority patent/FI121070B/fi
Priority claimed from FI20055258A external-priority patent/FI119373B/fi
Application filed by Bbs Bioactive Bone Substitutes Oy filed Critical Bbs Bioactive Bone Substitutes Oy
Application granted granted Critical
Publication of ATE533781T1 publication Critical patent/ATE533781T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/51Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT06743556T 2005-05-27 2006-05-26 Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten ATE533781T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FI20055256A FI118736B (fi) 2005-05-27 2005-05-27 Luun morfogeneettinen proteiini
FI20055257A FI121070B (fi) 2005-05-27 2005-05-27 Luun morfogeneettinen proteiini 6, sitä koodaava DNA, nukleotidivektori, rekombinantti isäntäsolu, farmaseuttinen koostumus ja osteogeeninen väline
FI20055258A FI119373B (fi) 2005-05-27 2005-05-27 Luun proteiineja
PCT/FI2006/050214 WO2006125868A1 (en) 2005-05-27 2006-05-26 Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof

Publications (1)

Publication Number Publication Date
ATE533781T1 true ATE533781T1 (de) 2011-12-15

Family

ID=37451667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743556T ATE533781T1 (de) 2005-05-27 2006-05-26 Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten

Country Status (4)

Country Link
US (1) US7910552B2 (de)
EP (1) EP1885751B1 (de)
AT (1) ATE533781T1 (de)
WO (1) WO2006125868A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101630501B1 (ko) 2010-08-20 2016-06-15 와이어쓰 엘엘씨 디자이너 골형성 단백질
WO2012029148A1 (ja) 2010-09-01 2012-03-08 株式会社オステオファーマ 組換えヒト骨形成タンパク質-2凍結乾燥製剤
CA2977625A1 (en) 2014-12-29 2016-07-07 Bioventus, Llc Systems and methods for improved delivery of osteoinductive molecules in bone repair
CN110092816B (zh) * 2018-01-29 2023-08-01 上海市第一人民医院 预防和治疗纤维化的小分子多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939388A (en) * 1986-07-01 1999-08-17 Rosen; Vicki A. Methods of administering BMP-5 compositions
US5459047A (en) 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
ES2113857T3 (es) 1989-03-28 1998-05-16 Genetics Inst Composiciones osteoinductoras.
WO1992005199A1 (en) 1990-09-26 1992-04-02 Genetics Institute, Inc. Bmp-5 derivatives
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US6083690A (en) 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US20030032586A1 (en) 1997-05-15 2003-02-13 David C. Rueger Compositions for morphogen-induced osteogenesis
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
WO2000029012A2 (en) 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms
DE19906096A1 (de) * 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20040253606A1 (en) 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
KR101013999B1 (ko) * 2004-03-19 2011-02-14 재단법인서울대학교산학협력재단 표면에 골조직 형성 증진 펩타이드가 고정된 차폐막 및임플란트

Also Published As

Publication number Publication date
US20100143433A1 (en) 2010-06-10
EP1885751A4 (de) 2009-04-01
US7910552B2 (en) 2011-03-22
WO2006125868A1 (en) 2006-11-30
EP1885751B1 (de) 2011-11-16
EP1885751A1 (de) 2008-02-13

Similar Documents

Publication Publication Date Title
ATE446313T1 (de) Muteine von tränen-lipocalin
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
ATE382053T1 (de) System zur antikörperexpression und- synthese
BR0210616A (pt) Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
BRPI0414880A (pt) métodos para intensificação da toleráncia ao estresse em plantas e composições das mesmas
AU2002305450A1 (en) Proteomimetic compounds and methods
NO20084362L (no) Difenylazetidinon derivater inneholdende kolesterol absorbsjonsinhibitor aktivitet
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
DE60120691D1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
EP1940861A4 (de) G-reiche polynukleotide zur behandlung von chorea huntington
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
ATE455783T1 (de) Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
WO2008100618A3 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE602005010270D1 (de) Von aminosäuren abgeleitete prodrugs von propofolzusammensetzungen und anwendungen davon
ATE533781T1 (de) Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten
ATE393573T1 (de) Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
WO2004094651A3 (en) Novel human polypeptides encoded by polynucleotides
ATE520711T1 (de) Knochenmorphogenetisches protein 4 und osteogene vorrichtungen und pharmazeutische produkte, die dieses enthalten